Beursonline.nl

[verwijderd] 18 november 2009 19:39

0

quote:
gocrucellgo schreef:
NOVEMBER 17, 2009, 1:30 P.M. ET.Common Cold Virus Linked to Failure of HIV Vaccine Test

Associated Press
WASHINGTON -- The failure of an experimental AIDS vaccine trial two years ago may have been caused by the common cold virus.

The vaccine was intended to block the spread of HIV, which causes AIDS. But the test was canceled after volunteers who got the shots were more likely to become infected than those who got a dummy shot.
................

Copyright © 2009 Associated Press
online.wsj.com/article/SB125840220390...

Niet best voor Crucell's Malaria en TB trials...

Adenovirus is also used in vaccines for tuberculosis and malaria that are under development, said Mr. Patterson, of Imperial College, London. This raises a particularly difficult problem in many areas of the world with a high rate of HIV, and high rates of TB and malaria that will be targeted by vaccines for those diseases, he said.

Dirk

z0n0p 18 november 2009 19:56

1

quote:
Dirk R. Wijnen schreef:
[quote=gocrucellgo]

NOVEMBER 17, 2009, 1:30 P.M. ET.Common Cold Virus Linked to Failure of HIV Vaccine Test

Associated Press
WASHINGTON -- The failure of an experimental AIDS vaccine trial two years ago may have been caused by the common cold virus.

The vaccine was intended to block the spread of HIV, which causes AIDS. But the test was canceled after volunteers who got the shots were more likely to become infected than those who got a dummy shot.
................

Copyright © 2009 Associated Press
online.wsj.com/article/SB125840220390...
[/quote]

Niet best voor Crucell's Malaria en TB trials...

Adenovirus is also used in vaccines for tuberculosis and malaria that are under development, said Mr. Patterson, of Imperial College, London. This raises a particularly difficult problem in many areas of the world with a high rate of HIV, and high rates of TB and malaria that will be targeted by vaccines for those diseases, he said.

Dirk

Is dit niet het Ad5 vs Ad35 verhaal. Verwijst dit niet naar het Merck HIV met Ad5 en is Ad35 niet van toepassing voor Malaria en TB.

z0n0p 18 november 2009 20:09

0

Ad5 en een verkoudheidje gingen niet samen.

Maar dit is het statement van Crucell daarover:

About AdVac® technology and Ad35
AdVac® technology is a vaccine technology developed by Crucell and is considered to play an important role in the fight against emerging and re-emerging infectious diseases, and in biodefense. The technology supports the practice of inserting genetic material from the disease-causing virus or parasite into a 'vehicle' called a vector, which then delivers the immunogenic material directly to the immune system. Most vectors are based on an adenovirus, such as the virus that causes the common cold.

The AdVac® technology is specifically designed to manage the problem of pre-existing immunity in humans against the most commonly used recombinant vaccine vector, adenovirus serotype 5 (Ad5), without compromising large-scale production capabilities or the immunogenic properties of Ad5. AdVac® technology is based on adenoviruses that do not regularly occur in the human population, such as Ad35. In contrast to for instance Ad35 antibodies, antibodies to Ad5 are widespread among people of all ages and are known to lower the immune response to Ad5-based vaccines, thereby impairing the efficacy of these vaccines. All vaccine candidates based on AdVac® are produced using Crucell's PER.C6® production technology.

[verwijderd] 19 november 2009 10:19

0

quote:
z0n0p schreef:
[quote=Dirk R. Wijnen]
[quote=gocrucellgo]

NOVEMBER 17, 2009, 1:30 P.M. ET.Common Cold Virus Linked to Failure of HIV Vaccine Test

Associated Press
WASHINGTON -- The failure of an experimental AIDS vaccine trial two years ago may have been caused by the common cold virus.

The vaccine was intended to block the spread of HIV, which causes AIDS. But the test was canceled after volunteers who got the shots were more likely to become infected than those who got a dummy shot.
................

Copyright © 2009 Associated Press
online.wsj.com/article/SB125840220390...
[/quote]

Niet best voor Crucell's Malaria en TB trials...

Adenovirus is also used in vaccines for tuberculosis and malaria that are under development, said Mr. Patterson, of Imperial College, London. This raises a particularly difficult problem in many areas of the world with a high rate of HIV, and high rates of TB and malaria that will be targeted by vaccines for those diseases, he said.

Dirk
[/quote]

Is dit niet het Ad5 vs Ad35 verhaal. Verwijst dit niet naar het Merck HIV met Ad5 en is Ad35 niet van toepassing voor Malaria en TB.

Klopt! Jaap Goudsmit kwam met die verklaring na het stopzetten van Merck´s Aids vaccine.
Crucell is verder gegaan met de ontwikkeling van het vaccin op basis van Ad35. Als deze verklaring nu wetenschappelijk bevestigd wordt, is dit weer een enorme prestatie an Crucell. Ben wel benieuwd op basis van welke gegevens de verklaring van Goudsmit nu bevestigd wordt. Is dit op basis van de gegevens van Merck destijds of de resultataten van Crucell bij de ontwikkeling van het Aids vaccin.
Mocht inderdaad blijken dat Ad35 de verklaring bevestigd dan kan Merck eerdaags weer aanhaken door het trekken van zijn portemonaye.

[verwijderd] 19 november 2009 11:37

0

Bedoelen ze hier nu alleen ad5 of alle adenovirussen.

Lees ook:

www.retrovirology.com/content/6/S3/P304

Dirk

[verwijderd] 19 november 2009 12:21

0

quote:
Dirk R. Wijnen schreef:
Bedoelen ze hier nu alleen ad5 of alle adenovirussen.

Lees ook:

www.retrovirology.com/content/6/S3/P304

Dirk

Recombinant adenovirus 26 vector avoids pre-existing immunity and is used in new HIV vaccine

Leiden, The Netherlands, 3 April 2008 - Dutch biotechnology company Crucell N.V. today announced that the novel recombinant adenovirus serotype 26 (rAd26) vector, which is jointly developed by Crucell and the Beth Israel Deaconess Medical Center (BIDMC), will be used in a phase I clinical study to test a new HIV vaccine. The rAd26 vector is specifically designed to avoid the pre-existing immunity to the more commonly used adenovirus serotype 5 (Ad5), which has recently shown limitations as an HIV vaccine vector.

The rAd26 vaccine is the first HIV vaccine candidate that emerges from the Integrated Preclinical/Clinical AIDS Vaccine Development (IPCAVD) program, which brings together researchers from academia and industry in an effort to accelerate the development of promising HIV/AIDS vaccines. Crucell, Harvard Medical School (HMS) and the BIDMC participate in this program, which is sponsored by the National Institutes of Health (NIH).

The phase I clinical study will be conducted at the Brigham and Women's Hospital (BWH) in Boston and will focus on assessing the safety and immunogenicity of the vaccine. The study will involve 48 healthy volunteers.

"The rAd26 vaccine vector has been selected for its particularly low seroprevalence in humans and for its potential immunogenicity and protective efficacy as was shown in preclinical studies", says Dan H. Barouch, MD, PhD, Associate Professor of Medicine at BIDMC and HMS and Principal Investigator in the IPCAVD program.

Jaap Goudsmit, Chief Scientific Officer at Crucell: "The rAd26 vector, as part of our AdVac® technology program, is designed to overcome the problem of pre-existing immunity in humans against the most commonly used recombinant vaccine vector, adenovirus serotype 5."

Antibodies to Ad5, a common cold virus, are widespread among people of all ages and are known to lower the immune response to Ad5-based vaccines, thereby impairing the efficacy of these vaccines.

"The rAd26 vector does not regularly occur in the human population and antibodies to this vector are rare. The rAd26 vector therefore is efficacious in eliciting good T and B cell responses", Goudsmit continues. "We are excited about the first in man study of this newly developed vector, that could provide a solution to the issues that raised from previous HIV vaccine trials."

flosz 20 december 2009 14:11

1

Feline ‘pawprint’ in HIV genome uncovered
December 9th, 2009 - 5:22 pm ICT by ANI

London, Dec 9 (ANI): Scientists from University of Rochester in New York claim to have found feline genetic “pawprint” in the modern-day form of the HIV virus.
They uncovered the genetic sequence in HIV genome that, they say, has descended from an ancient gene carried by lions or tigers over a million years ago.
According to lead researcher Robert Bambara, because the feline version of HIV - FIV - is an old virus, the newly discovered sequence might have been taken up by FIV from host lions or tigers, reports New Scientist magazine.

It is well known that virus started in cats, however, virologist Jaap Goudsmit claimed that ancient cats could have transmitted the virus to monkeys by licking or biting them.
Moreover, members of the cat family have shared their habitat with monkeys both in the East African wild and in Egyptian captivity, where monkeys were kept by the males of the household, while women kept cats.
The team led by Bambara approves that there are chances that HIV virus would have been passed on from ancient felines to monkeys, before being passed onto humans.
Matthew Portnoy of the National Institute of General Medical Sciences told HealthDay that the research could have ramifications for understanding the swine flu virus, which has also picked up genetic information from hosts of different species. (ANI)
www.thaindian.com/newsportal/health/f...

Feline 'pawprint' found in HIV genome
Jessica Hamzelou, reporter

African lions living over a million years ago may have carried an early form of HIV. Now, American microbiologists reckon they've found a feline genetic "pawprint" in the modern-day form of the virus.

Robert Bambara and his team at the University of Rochester in New York found a genetic sequence in the HIV genome that they think descended from an ancient gene.

The group reckon that, because the feline version of HIV - FIV - is an old virus, the newly discovered sequence might have been taken up by FIV from host lions or tigers over a million years ago.

The idea that the virus started in cats is not a new one. In 1998, virologist Jaap Goudsmit argued that ancient cats could have transmitted the virus to monkeys by licking or biting them.

Goudsmit pointed out that members of the cat family have shared their habitat with monkeys both in the East African wild and in Egyptian captivity, where monkeys were kept by the males of the household while women kept cats, both being signs of fertility.

Bambara and his team agree that it's likely the virus was passed from ancient felines to monkeys, before being passed onto humans.
www.newscientist.com/blogs/shortsharp...

Jaap Goudsmit Viral sex.
books.google.co.uk/books?id=WdE1WYH8Z...

voda 6 april 2010 16:32

0

Hiv is zijn eigen aanjager
6 april 2010, 9:20 | ANP
AMSTERDAM (ANP) - Hiv, het virus dat aids kan veroorzaken, gebruikt een afweerreactie van de eerste cellen die het virus in het lichaam tegenkomt om zichzelf te vermenigvuldigen. De afweerreactie, die normaal gesproken juist voorkomt dat een mens een infectie oploopt, zorgt ervoor dat hiv zich kan vermenigvuldigen.

Die ontdekking publiceert een groep onderzoekers van het Academisch Medisch Centrum (AMC) in Amsterdam dinsdag in het vooraanstaande wetenschappelijke tijdschrift Nature Immunology. De groep onder leiding van hoogleraar Teuynis Geijtenbeek noemt de ontdekking zelf ,,onverwacht''.

[verwijderd] 6 april 2010 22:09

0

Positief nieuws voor HIV. Wel even wachten tot september dit jaar.

Reason: This article is currently under embargo and will be available in PMC on September 1, 2010.

Mosaic HIV-1 Vaccines Expand the Breadth and Depth of Cellular Immune Responses in Rhesus Monkeys

Alvast een voorproefje:

The worldwide diversity of HIV-1 presents an unprecedented challenge for vaccine development. Antigens derived from natural HIV-1 sequences have elicited only a limited breadth of cellular immune responses in nonhuman primate studies and clinical trials to date. Polyvalent 'mosaic' antigens, in contrast, are designed to optimize cellular immunologic coverage of global HIV-1 sequence diversity.

Here we show that mosaic HIV-1 Gag, Pol and Env antigens expressed by recombinant, replication-incompetent adenovirus serotype 26 vectors markedly augmented both the breadth and depth without compromising the magnitude of antigen-specific T lymphocyte responses as compared with consensus or natural sequence HIV-1 antigens in rhesus monkeys. Polyvalent mosaic antigens therefore represent a promising strategy to expand cellular immunologic vaccine coverage for genetically diverse pathogens such as HIV-1.

harvester 6 april 2010 23:56

0

Besnijdenis van mannen voor beperking risico overdracht aids.

Bill Gates financiert het volgens zijn jnuari 2010 nieuwsbrief.

[verwijderd] 16 april 2010 21:17

0

Voorbereidingen worden getroffen voor een tweede onderzoek:
Evaluating the Safety and Immune Response of an Adenovirus-Based HIV Vaccine

1 Recruiting Safety of and Immune Response to an Adenoviral HIV-1 Vaccine in Healthy Adults Condition: HIV Infections
Intervention: Biological: Ad26.ENVA.01 HIV-1 vaccine

2 Not yet recruiting Evaluating the Safety and Immune Response of an Adenovirus-Based HIV Vaccine in HIV-Uninfected Adults Condition: HIV Infections
Interventions: Biological: Ad26.ENVA.01 (rAd26); Biological: Placebo Vaccine

www.clinicaltrials.gov/ct2/results?te...

flosz 30 april 2010 22:39

4

quote:
MeawandMoo1 schreef:
Positief nieuws voor HIV. Wel even wachten tot september dit jaar.

Reason: This article is currently under embargo and will be available in PMC on September 1, 2010.

Mosaic HIV-1 Vaccines Expand the Breadth and Depth of Cellular Immune Responses in Rhesus Monkeys

Alvast een voorproefje:

The worldwide diversity of HIV-1 presents an unprecedented challenge for vaccine development. Antigens derived from natural HIV-1 sequences have elicited only a limited breadth of cellular immune responses in nonhuman primate studies and clinical trials to date. Polyvalent 'mosaic' antigens, in contrast, are designed to optimize cellular immunologic coverage of global HIV-1 sequence diversity.

Zie ook post van 22 okt 09, 09:11 op pagina 20 www.iex.nl/Forum/topic.asp?forum=228&... met de presentatie van Dan Barouch.

*****************

Via de deurmat:
Antibody
Fever
Characterization of the slew of recently discovered
broadly neutralizing antibodies was one of the advances
highlighted at the recent HIV Vaccines conference
……….
The use of alternative Ad vectors such as Ad26
and 35 has been suggested for the development of
future candidate HIV vaccines, because of their
biological differences to Ad5 as well as lower levels
of preexisting immunity. Barouch presented
epidemiological data from Africa suggesting that
Ad26 and 35 antibody titers are substantially
lower than for Ad5, and seroprevalence to Ad26
and Ad35 is also less common than to Ad5. The
seroprevalence for these two vectors was less than
1% in 149 healthy two- to nine-month old South
African infants. Of 346 South African school
children age 6-18, 74% were seronegative for
Ad26, and 86% for Ad35, while only 31% were
seronegative for Ad5. And of 199 adults age 18-50
from several African countries, 58% were seronegative
for Ad26, and 78% for Ad35, while only
16% were seronegative for Ad5. “In total we
believe that these seroprevalence data support
proposals for further evaluation of these vectors
in Phase I trials in sub-Saharan Africa,” Barouch
said, adding that in preparation for clinical studies,
Ad26 and 35 vectors expressing mosaic Gag/
Pol/Env antigens are currently being manufactured
by the company Crucell. Mosaic antigens
are designed to achieve optimal coverage of the
many different versions of HIV proteins that are
circulating. “We hope to have these ready sometime
next year,” Barouch said.

investing in
Surprise
Efficacy trials may be costly, but some researchers
argue that they are the best way to advance
AIDS vaccine research and development

Determinants of cost
Not surprisingly, the single biggest factor that
drives the cost of a vaccine trial is the number of
enrollees. The more people that need to be recruited
and screened, and the more volunteers that need to
be tested, evaluated, and monitored over several
years, the more it costs to run the trial. Jerald
Sadoff, formerly chief executive of Aeras and now
chief medical officer at the Dutch biopharmaceutical
company Crucell NV, says the average total
study cost per subject is about $7,700 for a Phase II
or Phase IIb test-of-concept trial of a tuberculosis
(TB) vaccine candidate, an estimate he based on an
analysis of three TB vaccine studies. Based on this
estimate, it would cost about $12 million to conduct
a trial enrolling 2,200 individuals. Sadoff believes
the calculations are probably about the same for an
AIDS vaccine trial of similar size.
www.iavi.org/lists/iavipublications/a...

harvester 1 mei 2010 09:02

0

Uit post flosz: Barouch said,

adding that in preparation for clinical studies,
Ad26 and 35 vectors expressing mosaic Gag/
Pol/Env antigens are currently being manufactured
by the company Crucell.

Mosaic antigens
are designed to achieve optimal coverage of the
many different versions of HIV proteins that are
circulating. “We hope to have these ready sometime
next year,” Barouch said.

---------------
gaat dus de goede kant op en vermoedelijk horen wij hier volgend jaar meer van.

ved 13 mei 2010 18:11

1

From Medscape Medical News
HIV Vaccine Research a Field Apart From Classic Vaccinology
Bob Roehr

May 7, 2010 (Bethesda, Maryland) — HIV vaccine research is diverging from classic vaccinology and its focus on the adaptive immune response, to a field of its own. There has been a shift from protecting against infection to changing the nature of the infection, Anthony Fauci, MD, director of the National Institute of Allergy and Infectious Diseases (NIAID), in Bethesda, Maryland, said in his keynote address here at the National Foundation for Infectious Diseases 13th Annual Conference on Vaccine Research.

The principles of classic vaccinology are that "the response to natural infection is the guidepost to the vaccine. . . . The proof of concept is already done for us by the natural response to infection. . . . The vast portion of people spontaneously recover," he said.

"The virus is cleared and eradicated and the person is left with a protective immunity that, in most cases, is complete and lifelong."

But beginning with the gp160 trial in 1987, researchers quickly learned that the principles of classic vaccinology "didn't apply particularly well to HIV. . . . I've been taking care of HIV-infected individuals for almost 29 years and I have never seen anybody eradicate the virus or spontaneously recover," Dr. Fauci said.

"And protective immunity against subsequent infection doesn't appear to occur. That is amazing. You are infected with a microbe and, while you are infected, you get reexposed to the microbe and you get reinfected. That is depressing for vaccinologists."

"There is no proof of concept to help us. We really have to start from scratch," he said. Basic research has been able to generate a few antibodies that are broadly neutralizing to laboratory strains of HIV, but not to wild-type virus, Dr. Fauci noted.

Once these facts began to sink in, the field shifted toward developing a vaccine that would not protect against infection but that might shift the course of disease progression to one that is less lethal, perhaps even benign. The public health goal of reducing transmission might be accomplished by lowering the viral load of those who are infected. "Those attempts, thus far, have not been successful," Dr. Fauci said.

STEP Back

The early stopping of the STEP trial, which was testing an HIV vaccine developed by Merck with the support of NIAID, led the field to another reevaluation. The mix of basic and developmentally oriented research was recalibrated back toward the former.

Then came the Thai study (RV144) "using a pox virus vector and an envelope boost, which, when you looked immunologically, had virtually none of the classical parameters that would predict protection. [Cytotoxic T lymphocytes] were nowhere to be found; neutralizing antibody, nowhere to be found," Dr. Fauci said.

But "for the first time we found a modest, weak, but real signal of prevention of acquisition," he said. "There was no doubt that the Kaplan–Meier curves were separated. We now had a weak signal upon which to build."

The fact that the vaccine had no effect on the viral load of those who became infected confounded the expectations of many, but not Dr. Fauci.

"I think it argues for the dichotomy of effect on acquisition vs the control of chronic viral infection. It is telling us something that perhaps we should have realized a long time ago — an immune response that protects against acquisition might be quite different from the immune response that actually controls chronic virus replication."

"What we have now is a whole new way of looking at things. . . . We really know what is going on and what is needed."

He sees the way forward as building on the empiricism of the RV144 trial while, at the same time, pursuing the fundamental issues of basic research.

Dr. Fauci is not sure that it will be possible to isolate correlates of protection from acquisition from the small number of infections in the Thai trial, "but it certainly will tell us what they are not. And what they aren't is 750 ELISPOTS on an assay. What they aren't is broadly cross-reacting neutralizing antibodies. . . . It may be that they are important, but they are not a requirement."

Different Virus

"As scary and dangerous as HIV infection is, it is a very inefficiently transmitted infection. One of the reasons is that there is a bottleneck to transmission." It has become apparent that "the transmitting virus might be quite different from the chronic replicating virus."

The transmitting virus appears to have a unique hypoglycosylated molecular signature that, surprisingly, appears to be easier to neutralize than variants found later in infection. However, once infection is established, the virus rapidly diversifies with conformational changes and the addition of glycands that can shield antibody binding sites, and the virus evades immune control.

Dr. Fauci pointed to the work of Dennis Burton, showing that "when looking at acquisition, you really need low levels of neutralizing antibody, much lower than you would have predicted" from the study of established infections. "There is a direct correlation between the ease of neutralization of a transmitting virus [and] the virus that has been replicating for years."

He added that "as the quasi-species develops, the virus diverges. The further you are from infection, the more divergent the virus is; the closer you are to the initial infection, the more homogeneous the virus is."

"Once the virus robustly replicates and gets into the lymphoid tissue, for all practical purposes, the ballgame is over for a vaccine. No matter what we do, you don't eradicate the virus. . . . The focus really needs to be on blocking acquisition. That is the end game."

It is why he is focusing on very early events, far earlier than the adaptive immune system is capable of reacting to.

Dr. Fauci indicated that, taken together, the cytotoxic T lymphocyte response will play, at best, a small role in future research toward a preventive vaccine. It might have some role in immunotherapy for HIV disease, but his comments on the effectiveness, tolerability, and cost of available small-molecule drugs create a high bar in moving HIV immunotherapy from basic research into regular clinical practice.

Dr. Fauci has disclosed no relevant financial relationships.

National Foundation for Infectious Diseases (NFID) 13th Annual Conference on Vaccine Research: Session 8. Presented April 27, 2010.

www.medscape.com/viewarticle/721410

[verwijderd] 18 juni 2010 13:11

0

GlaxoSmithKline: Treatment For Infants And Children In Asia
Last update: 6/18/2010 6:26:29 AM

("GlaxoSmithKline, Amfar Form Pact To Optimize HIV Treatment In Asia," at 1305 GMT Thursday, incorrecly said GlaxoSmithKline and Amfar had formed a pact in the lead and headline.The correct version follows:)

LONDON (Dow Jones)--ViiV Healthcare and amfAR Thursday announce a two year partnership that aims to improve access and optimize the quality of healthcare for infants and children living with HIV across Asia.

MAIN FACTS: -$2 million initiative created to generate clinical evidence and develop strategies to support life-long paediatric care and help inform global treatment guidelines.

-ViiV Healthcare is a global specialist HIV company established by GlaxoSmithKline (GSK) and Pfizer (PFE) to deliver advances in treatment and care for people living with HIV

-By Ian Walker, Dow Jones Newswires; 44-20-7842-9296; ian.walker@dowjones.com (END)

Dow Jones NewswiresJune 18, 2010 06:26 ET (10:26 GMT)

DRW

diederique 18 juli 2010 23:24

0

July 18 (Reuters) -

A major international conference on AIDS starts in Vienna on July 18, when thousands of scientists, health workers, activists, and government officials will gather to discuss the latest advances against the disease.

www.reuters.com/article/idUSLDE66D13E...

diederique 18 juli 2010 23:31

0

...Amsterdam-based Crucell NV (CRCL.AS) is another example. The company is in early stages of human testing of a vaccine made using a virus that carries pieces of HIV DNA........

www.reuters.com/article/idUSN17159653

================

quote:
diederique schreef:
July 18 (Reuters) -

A major international conference on AIDS starts in Vienna on July 18, when thousands of scientists, health workers, activists, and government officials will gather to discuss the latest advances against the disease.

www.reuters.com/article/idUSLDE66D13E...

diederique 19 juli 2010 19:34

0

Two-step vaccine may offer "universal" flu jab

.........."We are excited by these results," Nabel said. "The prime-boost approach opens a new door to vaccinations for influenza that would be similar to vaccination against such diseases as hepatitis, where we vaccinate early in life and then boost immunity through occasional, additional inoculations in adulthood."

The vaccine, which uses DNA from Netherlands-based *****Crucell NV*****, "looks pretty safe," Fauci said. "They are already well into, at least a full year into, a Phase 1 trial."

Such trials are meant to see if a new drug or vaccine is safe in people. A larger, Phase 2 trial could start next year, Fauci said.

www.reuters.com/article/idUSTRE66E7BM...

voda 20 juli 2010 15:32

1

Doorbraak: gel helpt hiv-infectie te voorkomen

KAAPSTAD - Wetenschappers spreken van een doorbraak; voor de eerste keer is een vaginale gel in staat gebleken het aidsvirus tegen te houden. Uit een studie in Zuid-Afrika bleek dat de gel de kans op hiv bij vrouwen met een geïnfecteerde partner met vijftig procent verminderde.

De resultaten moet nog bevestigd worden in een andere studie en de mate van bescherming is wellicht niet voldoende om de gel toe te staan in landen als de Verenigde Staten, maar onderzoekers zijn er optimistisch over dat de gel nog verbeterd kan worden.

De gel met de aidsmedicijn tenofovir verminderde de kans op hiv met vijftig procent na gebruik van één jaar en met 39 procent na tweeënhalf jaar, vergeleken met gels zonder medicijnen. Om toegestaan te worden in de VS moet een gel of crème die hiv voorkomt voor ten minste tachtig procent effectief zijn.

Dat kan bereikt worden als er meer tenofovir aan de gel wordt toegevoegd of als vrouwen de gel vaker gebruiken. De vrouwen in de studie gebruikten de gel zestig procent van de keren dat ze gemeenschap hadden, vrouwen die het vaker gebruikten bleken ook een hogere graad van bescherming te hebben.

Zelfs gedeeltelijke bescherming is een enorme overwinning die niet alleen voor arme landen een zegen kan zijn, maar ook voor stellen overal ter wereld van wie één hiv heeft en de ander niet, aldus Salim Abdool Karim, de Zuid-Afrikaanse onderzoeker die de studie leidde. Hij zal de resultaten dinsdag presenteren op de internationale aidsconferentie in Wenen. (Novum/AP)
19/07/10 21u57

Lees ook: Kwart meer aidspatiënten krijgt behandeling
Lees ook: Geldzorgen op Internationale AIDS Conferentie
Lees ook: Minder hiv door veilige seks jongeren Afrika

www.ad.nl/ad/nl/1015/Gezondheid-weten...

flosz 7 augustus 2010 10:34

2

Mucosal Trafficking of Vector-Specific CD4+ T Lymphocytes Following Adenovirus Serotype 5 Vaccination of Rhesus Monkeys
....

These findings from this nonhuman primate model provide evidence against the hypothesis that recruitment of vector-specific target cells to mucosal sites led to increased HIV-1 acquisition in Ad5 seropositive, uncircumcised vaccinees in the Step study
tinyurl.com/3y2m3zp

AEX 923,36 +4,69 +0,51% 06 jun


Germany40^	18.636,40	-0,09%
BEL 20	3.916,97	+0,26%
EURO50	5.070,61	+0,29%
US30^	38.871,60	0,00%
Nasd100^	19.018,90	0,00%
US500^	5.352,88	0,00%
Japan225^	38.635,50	0,00%
Gold spot	2.376,36	+0,89%
EUR/USD	1,0893	+0,20%
WTI	75,57	+1,94%

BESI	+2,97%
ASR Nederland	+2,88%
ABN AMRO BANK...	+1,54%
ASML	+1,47%
ING	+1,36%

FASTNED	-2,86%
NX FILTRATION	-2,65%
VIVORYON THER...	-2,45%
PostNL	-1,90%
Basic-Fit	-1,88%

Crucell « Terug naar discussie overzicht

Draadje HIV/AIDS

Meedoen aan de discussie?

Direct naar Forum

Markt vandaag

Aandelenadviezen van IEX.nl

Stijgers

Dalers